Effect of an organized lipid matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis.
OBJECTIVE
To compare the absorption of a lysophosphatidylcholine, monoglyceride, and fatty acid matrix (organized lipid matrix, OLM) with that of a triacylglycerol (TG)-based fat meal in patients with cystic fibrosis (CF).


METHODS
Five adolescents with CF and 3 control patients were given fat meals supplemented with retinyl palmitate of either OLM or TG at a 2-week interval. In a clinical trial, 73 patients with CF were randomly assigned to nutritional supplements containing either OLM or TG for a 1-year double-blind trial followed by a 6-month observation period.


RESULTS
The peak increases and areas under the curve for TG and retinyl palmitate after the fat meal were 10-fold higher after OLM than after the TG fat load and did not differ from values obtained in control patients. OLM led to better clinical outcomes in terms of energy intake from the diet, weight-for-age Z score, essential fatty acid status, vitamin E, and retinol binding protein. Height-for-age Z score and FEV(1) only reached statistical significance at the end of the 6-month observation period.


CONCLUSIONS
These results suggest that OLM is a readily absorbable source of fat and energy in CF and is an effective nutritional supplement.
Department of Pediatrics, Hôpital Ste-Justine, Université de Montréal, Québec, Canada.
Guy
G
Lepage
David W
DW
Yesair
Nancy
N
Ronco
Josée
J
Champagne
Nathalie
N
Bureau
Sylvain
S
Chemtob
Denis
D
Bérubé
Claude C
CC
Roy
D000293:Adolescent; D000328:Adult; D000886:Anthropometry; D019540:Area Under Curve; D002170:Canada; D002648:Child; D002669:Child Welfare; D003550:Cystic Fibrosis / Q000178:diet therapy*; D004041:Dietary Fats / Q000378:metabolism* / Q000627:therapeutic use*; D004224:Diterpenes; D004311:Double-Blind Method; D015777:Eicosanoids / Q000097:blood; D002149:Energy Intake / Q000187:drug effects; D005227:Fatty Acids / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology*; D008099:Liver / Q000201:enzymology; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D010349:Patient Compliance; D012177:Retinol-Binding Proteins / Q000378:metabolism; D000084562:Retinyl Esters; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D014801:Vitamin A / Q000031:analogs & derivatives / Q000097:blood; D014815:Vitamins / Q000097:blood; D019207:beta Carotene / Q000097:blood
D004041:Dietary Fats; D004224:Diterpenes; D015777:Eicosanoids; D005227:Fatty Acids; D012177:Retinol-Binding Proteins; D000084562:Retinyl Esters; D014280:Triglycerides; D014815:Vitamins; D019207:beta Carotene; D014801:Vitamin A; C014794:retinol palmitate; D008315:Malondialdehyde